cyrilzakka/clinical-trials huggingface dataset:
Miller Straight Blade vs Macintosh Blade

The purpose of this prospective open labeled randomized study was to compare the "laryngoscopic glottis view" as well as "ease of intubation" between the two blades in routine intubations in non-difficult airways.

One hundred and fifty patients with predicted non difficult airway were randomly assigned into two groups. After induction of anaesthesia laryngoscopy was performed with respective blades and trachea intubated. Parameters monitored were: glottis view obtained during laryngoscopy (Cormack Lehane grade), ease of intubation, intubation attempts, total duration of laryngoscopy in seconds and encountered complications.

Eligibility Criteria:
Inclusion Criteria:

* All ASA I \& II grade patients undergoing elective surgery requiring general anesthesia with oral endotracheal intubation

Exclusion Criteria:

* Patients with anticipated difficult airway
* Cervical spine disorders
* Anesthesia requiring rapid sequence induction
Anesthesia Feasibility Study With the CONCERT-CL® Station

This is a feasibility study of anesthesia in closed loop with the CONCERT-CL® station, on the effect of the hypnotic agent, measured by the bispectral index of the electroencephalogram, to maintain the hypnosis level within the recommended limits for general anesthesia. The analgesic agent is administered in "Target-Controlled Infusion = TCI" and analgesia evaluated by pupillometry.

This is a prospective, open, non-controlled, non-randomized, monocentric study. The main objective is to study the potential contribution of the system in the conduct of anaesthesia, as decision support, for the administration of the hypnotic agent.

Secondary objectives will include hemodynamic stability, and the average concentrations of opioid and hypnotic anesthetic agents evaluated from the pharmacokinetic model.

The study will involve surgical patients scheduled for surgery under general anesthesia for more than 1 (one) hour.


Eligibility Criteria:
Inclusion Criteria:

* men and women aged 18 years old and over
* Surgery of any type programmed for longer than 1 hour
* Anesthesia combining three agents: hypnotic, morphine, curare

Exclusion Criteria:

* minor patient
* pregnant and lactating women
* Known or suspected hypersensitivity to propofol,
* known or suspected hypersensitivity to remifentanil and other fentanyl derivatives,
* known or suspected hypersensitivity to rocuronium and atracurium, preventing the use of the two products.
* peanut allergy, soy, Egg
* neurological disease history with known modification of the electroencephalogram
* severe eye disease, ocular implant, standing diabetes with diabetic retinopathy
* gravis
* pacemakers patient
* surgery whose position is not suitable for a monitoring on the ulnar nave
* general anesthesia associated with regional anesthesia
* Simultaneous use of shortwave therapy or microwave
* Simultaneous use of high frequency surgical apparatus
* 15 patients under supervision or unable to consent
* patient undergoing psychiatric care
* patient in a health or social institution
* emergency
A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

The main purpose of this study is to test if LY2951742 relieves mild to moderate knee pain. The study drugs will be given as an injection under the skin and as an oral capsule. The study will last about 28 weeks for each participant.


Eligibility Criteria:
Inclusion Criteria:

* Have osteoarthritis (OA) of the knee joint based on American College of Rheumatology (ACR) criteria and confirmed with X-rays and ACR functional class of I to III
* Have been on stable dose of prescription Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), celecoxib, tramadol, or acetaminophen of at least 2000 mg per day for at least 20 days in the past month
* Willing to stop all analgesics for OA pain during the study
* Experienced pain while walking in the target knee of 50-90 mm inclusive on 0-100 Visual Analog Scale (VAS) with an increase in pain while walking of at least 10 mm following washout of current Osteoarthritis pain medications at screening

Exclusion Criteria:

* Allergic to LY2951742, celecoxib, other NSAIDS, including aspirin, and similar drugs
* Arthritis of the knee from other causes
* Uncontrolled hypertension
* Have OA pain that requires treatment with potent opioids, systemic corticosteroids, intra-articular injections, duloxetine, or venlafaxine
* Moderate to severe renal impairment
* Pregnant or lactating
Velcade in MALT Lymphoma Patients

Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.

The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation.

It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.

Eligibility Criteria:
Inclusion Criteria:

* patients with histologically confirmed MALT lymphoma with measurable disease (stage I-IV)
* with first or greater relapse after HP-eradication, radiation or chemotherapy ,
* age \> 18 years
* must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
* ECOG status of \<_ 2
* must be capable of understanding the purpose of the study and given written informed consent
Investigation of Fat Oxidation During Moderate Versus Vigorous Intensity Exercise

Exercise is widely suggested as an important lifestyle change for weight loss, however, the optimal level of intensity moderate versus vigorous remains unclear. It is known that in athletes, during very high-intensity exercise, fat oxidation is decreased and energy is gained mainly from carbohydrate utilization. The aim of this study is to find an optimal workload based on fat oxidation rate during exercise in volunteers with a sedentary lifestyle.

It is planned to recruit 12 healthy volunteers with a sedentary lifestyle in the study group. Since different regimens (fed, fasted and moderate versus vigorous) will be compared in the same subjects, no control group is necessary. Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected after the incremental intensity exercise). The expiration of carbon dioxide (CO2) and consumption of oxygen (O2) will be measured, to determine the total fatty acid and carbohydrate oxidation during cycling. Concomitantly, it is planned to measure blood lactate and glucose concentrations during exercise experiments as well as a wide range of blood biochemistry parameters before and after exercise.

The investigators expect to find optimal conditions for the sedentary population for burning of fat, which is the major source of energy during moderate-intensity exercise. Measurements of the fat and carbohydrate oxidation in healthy volunteers with a sedentary lifestyle will contribute to the understanding of exercise regimens for the most effective fat oxidation.

Eligibility Criteria:
Inclusion Criteria:

* Healthy
* Sedentary lifestyle
* BMI 20 - 30 kg/m2
* Be able to attend the laboratory and willing to participate in necessary protocols
* Be willing to undertake the duration of the exercise protocol (3 x 1 hour)
* Have the capacity and willingness to provide informed consent (oral and written)

Exclusion Criteria:

* athletes
* Individuals with chronic cardiovascular disease such as hypertension, valve disease, coronary artery disease, cardiac conduction abnormalities, etc.
* History of pneumothorax or chronic lung disease such as asthma, COPD, bronchiectasis
* Active Smokers
* Pregnant women
Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

This study is collecting post-marketing information on the safety and effectiveness of Ventavis under the routine clinical practice for patients with PAH

This local, prospective, non-interventional, company sponsored, multi-center, single-cohort study includes patients treated with Ventavis for PAH. A total of 270 patients (valid for safety analysis) is planned to be enrolled in 5 years. Target population is patients with PAH diagnosis. This study is performed as an all-patient investigation, therefore all patients who receive Ventavis treatment for PAH need to be registered. The treatment should be performed based on the product label in Japan. The standard observation period will last for 12 months from starting Ventavis treatment. In addition, the extension observation will be carried out as long as Ventavis treatment continues or at most for more 4 years. The standard observation points are 3 month and

1 to 5 years.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with PAH
* Patients for whom the decision to initiate treatment with Ventavis was made as per investigator's routine treatment practice.

Exclusion Criteria:

- N/A
Oral Glucose Tolerance Test and Post Partum Diagnosis of Diabetes Mellitus, Type 2 (DT2 Post-Partum)

Diabetes mellitus, type 2, is a chronic disease which can be linked with many complications in connexion with impaired blood glucose balance.

It diagnosis in risky subjects such as in patients with medical history of gestational diabetes is therefore imperative to prevent its complications.

Actual guidelines recommend an oral tolerance glucose test, measuring glucose levels after oral glucose intake (75g), between 6 an 12 weeks after childbirth. But studies reveal a low diagnosis rate.

The study of the current practices of diagnosis methods seem to be essential in order to improve this diagnosis.


Eligibility Criteria:
Inclusion Criteria:

* Patients followed in endocrinology at the hospital of Vienne for gestational diabetes, whom benefited an educational therapy session between the 01/01/2016 and the 31/12/2016 inclusive.

Exclusion Criteria:

* Minor patients or under legal protection (guardianship)
* Patients who not speak french
* Patients who did not declared an attending physician
* Refusal to take part in the survey
* Patients lost to follow-up before childbirth
* Patients whose pregnancy ended by foetal death.
* Pre-existing diabet before pregnancy
Test Retest Reliability of OA and OH

The goal of this study is to measure the test retest reliability of offset analgesia (OA) and onset hyperalgesia (OH) across multiple study visits. OA and OH are quantitative sensory tests (QST) thought to measure how the brain modulates pain. This study will use a heat thermode to induce OA and OH in healthy, pain-free volunteers across 3 study visits. Additional QST measures and survey data relevant to pain modulation will be collected. This study lays the foundation required to use OA and OH as tools to measure pain modulation in clinical trials. Following their validation, we anticipate that OA and OH will serve as predictive and therapeutic biomarkers, which will aid both in the development of novel analgesics and in treatment selection leading to the personalization of pain management.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers with no chronic pain issues who can understand the study procedures

Exclusion Criteria:

* History of chronic pain
* Current significant pain disorder
* Active ongoing pain every day that is acute or chronic in duration
* Recent history of migraine (1 attack in last 24 months)
* Lifetime history mood disorders (anxiety, depression, bipolar) or psychotic disorders.
* Subjects taking psychotropics (e.g. benzodiazepines, antidepressants), or medications known to affect the autonomic nervous system (e.g. beta-receptor agonists or antagonists) will be excluded.
* Cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures
* Uncontrolled or unstable medical disorder preventing participation in study procedures
* Pregnancy
* Tattoos on forearm
* History of brain surgery
* Nonambulatory status
* Heart problems such as an irregular heart beat or coronary artery disease
* Neurological problems such as seizure, fainting spells, recurrent severe headache, stroke, transient ischemic attack
* High blood pressure
* Severe liver disease
* Severe gastrointestinal disease
* Chronic severe infectious disease (e.g. HIV/AIDS)
Affective Touching on Poststroke Depression

This mixed-method study includes a randomised controlled trial and an exploratory qualitative study, and aims to examine the effects of caregiver-delivered affective touch on depressive symptoms, state of attachment security, self-esteem, and perceived family harmony among stroke survivors, and to explore the mediating effect of attachment security and how an intervention may affect depressive symptoms from stroke survivor's perspective. A total of 184 survivor-caregiver dyads will be recruited from various non-governmental organisations. The dyads will be randomly allocated to intervention (IG) and control (CG) groups, stratified by the survivor's attachment style. IG caregivers will be taught to deliver a 15-minute affective touch intervention to stroke survivors. To address the attention effect, CG caregivers will be asked to sit with the survivors during a 15-minute fine motor coordination exercise. Both activities, affective touching and fine motor exercise, will be performed for 12 weeks (3 times/week), and the outcomes mentioned earlier will be measured at baseline, 12 and 36 weeks after study entry.


Eligibility Criteria:
Inclusion Criteria:

1. Stroke survivor-caregiver dyads

   * Hong Kong residents, aged 18 years or above,
   * able to understand and give informed consent \[Abbreviated Mental Test (Hong Kong version) score ≥6\].
2. Stroke survivors

   * within the first three months of being diagnosed with first-onset acute ischemic/haemorrhagic stroke,
   * able to comprehend verbal instructions,
   * with premorbid depressive symptoms \[20-item Centre of Epidemiology Studies Depression Scale score ≥8\].
3. Family caregivers

   * family members who assume the primary responsibility for caring for a stroke survivor and who are identified by the survivors as their primary caregivers,
   * live with the survivors and provide care ≥4 hours/day,
   * have no history of self-reported or medical diagnosis of psychiatric illness,
   * are able to learn and willing to provide the intervention.

Exclusion Criteria:

* Stroke survivor-caregiver dyads who are not Chinese
Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy

The study's purpose is to understand the self-management needs of patients with NSCLC receiving targeted therapy, develop a disease self- management application (mHealth Application), and explore the effect of mHealth application on the self-efficacy and health status of patients receiving targeted therapy for NSCLC.

This study adopts a two-group (pre-and-post-test) design experiment. This study is being conducted over a period of 3 years and is divided in two stages. This study enrolled patients with NSCLC in the outpatient clinic and ward of the Division of Chest Medicine in a northern medical center as the research participants. Stage 1 develop a disease self-management application and understands participants' needs by qualitative study. The participants are a purposive sample of 15-20 patients. Data discontinued when theme saturation is achieved. Stage 2 adopted convenient sampling to enroll 108 patients (54 in the experimental group and 54 in the control group) to evaluate the effectiveness of the disease self-management application. After participant's consent was obtained, this study performed the pre-test and randomized the participants. The experimental group received both routine care and the disease self-management App, while the control group received routine care and part of application. This study collected data before the patients received targeted therapy and in months 1, 3, 6, and 9 after treatment initiation.


Eligibility Criteria:
Inclusion Criteria:

* ≧20 years of age
* diagnosed with advanced NSCLC
* were epidermal growth factor, anaplastic lymphoma kinase...inhibitor-naive

Exclusion Criteria:

* had received other anti-cancer therapy
* were difficulty with verbal expression or cognitive dysfunction
Stem Cell Therapy in Spinal Cord Injury

The purpose of this study is to study the effect of stem cell therapy on common symptoms in patients with spinal cord injury.

Autologous bone marrow mononuclear cells are administered intrathecally by a standard procedure followed by vigorous rehabilitation therapy.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed cases of any type of spinal cord injury
* age above 12 months.

Exclusion Criteria:

* presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus
* malignancies
* bleeding tendencies
* pneumonia
* renal failure
* severe liver dysfunction
* severe anemia \[Hemoglobin \< 8\]
* any bone marrow disorder
* space occupying lesion in brain
* other acute medical conditions such as respiratory infection and pyrexia.
Clinical Effectiveness and Safety of a Novel Oral Rehydration Solution

This is a randomised, controlled, open-label study to determine the clinical effectiveness and safety of a novel ORS compared with a commercial ORS in children 1 to 5 years of age attending emergency departments with gastroenteritis.


Eligibility Criteria:
Inclusion Criteria:

* 1 to 5 years of age, inclusive at randomization
* Hospitalized with mild to moderate dehydration due to ongoing diarrhea
* Signed informed consent obtained for child's participation in the study

Exclusion Criteria:

* Severe dehydration and/or use of IV fluids for current hospitalization
* Experiencing bloody diarrhea or diarrhea due to Cholera, Dysentery, persistent/chronic diarrhea, diarrhea with severe malnutrition, diarrhea associated with recent antibiotic use
* In the opinion of the Investigator, not suitable for treatment with ORS
* Have any underlying disease or disorder that may, in the opinion of the Investigator, affect the results of the study if they were enrolled (includes, but is not limited to, gastrointestinal disorders such as Crohn's disease or other inflammatory bowel disease or congenital malabsorption disorders)
* Cause of the dehydration is something other than diarrhea
* Known to be allergic to any of the components of the Investigational ORS
Differential Effects of Protein Quality on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes: Comparison of Whey, Casein, Gluten, and Cod Protein

Enhanced and prolonged postprandial triglyceride responses involve increased cardiovascular risk in type 2 diabetes. It has been demonstrated that dietary fat and carbohydrates profoundly influence postprandial hypertriglyceridemia in type 2 diabetes, whereas little information exists about the effect of proteins.

The purpose of this study is to compare the effects of the proteins casein, whey, cod, and gluten on postprandial lipid and incretin responses to a high-fat meal in type 2 diabetes.


Eligibility Criteria:
Inclusion Criteria:

* Diabetes

Exclusion Criteria:

* Liver, Kidney- and/or Heart Disease
* Serious Hypertension (160/110 mmHg)
An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

This is a descriptive, prospective, observational and epidemiological study on participants recently diagnosed with breast cancer to evaluate the HER2 status by IHC and SISH procedures.


Eligibility Criteria:
Inclusion Criteria:

- Anatomopathological samples (surgical specimens or when a surgical sample is not possible, a core needle biopsy may be used) from female participants with a histopathological diagnosis of invasive breast cancer

Exclusion Criteria:

* Samples whose residual material in the paraffin block(s) is insufficient for neoplasm representation in the procedures in this study
* Cancer samples that have received previous chemotherapy treatment
Community Study to Reduce High Blood Pressure Through Text Messaging (REACH OUT)

One of the most powerful predictors of stroke is hypertension, with estimates of approximately 33% of adults in the United States experiencing this condition. Hypertension is significantly more prevalent in African Americans compared to European Americans. Importantly, hypertension is a modifiable stroke risk factor.

This proposal will use a community-based participatory research approach to perform a randomized trial of a mobile phone text-messaging intervention to reduce high blood pressure in an urban African American community in Flint, Michigan.

This is a randomized controlled trial of text messaging and blood pressure self-monitoring to reduce blood pressure.

Eligibility Criteria:
Inclusion Criteria:

* Adult (\>18 y/o) participants with BP ≥140/90 who have mobile phones with text-messaging capability.

Exclusion Criteria:

* Adult who is illiterate, non-English speaking, pregnant, incarcerated/ institutionalized resident, or has a pre-existing condition that makes follow-up for 6 months unlikely.
Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage

The purpose of this study is to investigate whether zoledronic acid-loaded bone cement (4mg ZOL+ gentamicin PMMA ) as adjuvant method can decrease local recurrence in patients with giant cell bone tumor following intralesional curettage surgery. The hypothesis is that patients with local administration of zoledronic acid to the bone cement has lower relapse rate compared those with traditional bone cement(gentamicin PMMA ).

The purpose of the clinical study is to investigate whether the local delivery of zoledronic acid (4mg ZOL-loaded gentamicin PMMA bone cement) as a surgical adjuvant can decrease the local recurrence rate of giant cell tumor (GCT) of bone. The investigators will also evaluate whether patients with zoledronic acid as a surgical adjuvant improves secondary outcomes, including function (MSTS and TESS), surgery related complications (henderson's failure mode) and ZOL-related complications.

Eligibility Criteria:
Inclusion Criteria:

* patients with primary resectable GCT of bone
* lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal
* no previous systemic bisphosphonate or denosumab therapy
* with expected longer than 18 months of survival time
* sign the informed consent form

Exclusion Criteria:

* patients with recurrent GCT or extensive GCT which is impossible or inappropriate to use curettage surgery due to its "unresectable" nature.
* conduct unexpected surgery at other center
* the primary goal for surgery is revision
* patient conduct en-bloc/wide resection instead of curettage surgery
* patient can not conduct self-assessment during follow up
* difficulty in complete postoperative follow-up
* previous use of bisphosphonate/ZOL or denosumab drug
* patients have participated in similar research projects
* refused to sign informed consent